{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:51:00Z","timestamp":1792788660567,"version":"4.5.0"},"update-to":[{"DOI":"10.12688\/wellcomeopenres.26002.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000}}],"reference-count":40,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wellcome Trust\/DBT India Alliance","award":["IA\/CPHI\/14\/1\/501514"],"award-info":[{"award-number":["IA\/CPHI\/14\/1\/501514"]}],"id":[{"id":"https:\/\/ror.org\/04reqzt68","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["wellcomeopenresearch.org"],"crossmark-restriction":false},"short-container-title":["Wellcome Open Res"],"abstract":"<ns3:p>Background Stroke is the second leading cause of death globally. We tested whether it was feasible to deliver a community-based intervention package for prevention of stroke and, whether such an intervention would reduce stroke mortality in a rural underserved community in central India. Methods In this two-arm, parallel group, open label, cluster randomised controlled trial, 64 villages were randomly assigned with 1:1 allocation to the control and the intervention arm in a demographic surveillance site. The intervention was delivered for 3.5 years. It included community-based screening for hypertension, diabetes and stroke among individuals \u2265 50 years of age by trained community health workers followed by village-based treatment by an outreach physician, awareness generation and active follow up. In the control arm, households were provided information on the ill effects of tobacco and steps to quit it. Cause of death was ascertained on all deaths using verbal autopsies by physician coders who were blinded to the treatment allocation. Results There were 7671 individuals in the control arm and 8255 in the intervention arm who were \u2265 50 years of age. In the intervention arm, out of 8255 eligible individuals, 8026 were screened and 2793 were diagnosed with hypertension, 317 with diabetes and 182 with stroke and those with these three conditions received the intervention. The stroke mortality rate per 100,000 person-years in the last 2.5 years of the intervention, which was the primary outcome of the trial, was comparable in the intervention (416.7) and the control arm (484.9) (adjusted hazard ration [HR] 0.84, 95 % confidence interval [0.62,1.12]; p = 0.23). Important limitations include limited access to brain imaging and lipid profile measurements. Conclusions In this under resourced rural community in central India, a community-based intervention for stroke risk reduction did not reduce stroke mortality over the final 2.5 years of the trial. However, the trial intervention was acceptable and led to improved medication compliance, blood pressure control and awareness about stroke. Trial registration The trial was registered at the Clinical Trials Registry of India: CTRI\/2015\/12\/006424.<\/ns3:p>","DOI":"10.12688\/wellcomeopenres.26002.2","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:49:08Z","timestamp":1783493348000},"page":"209","update-policy":"https:\/\/doi.org\/10.12688\/wellcomeopenres.crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of a community-based intervention for cardiovascular risk factor control on stroke mortality in rural Gadchiroli, India: a cluster-randomised controlled trial"],"prefix":"10.12688","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3543-3618","authenticated-orcid":false,"given":"Yogeshwar","family":"Kalkonde","sequence":"first","affiliation":[{"name":"Gadchiroli Maharashtra Stroke Trial Project Gadchiroli"},{"name":"Ambikapur Chhattisgarh Sangwari, People's Association for Equity and Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Jadhao","sequence":"additional","affiliation":[{"name":"Gadchiroli Maharashtra Stroke Trial Project Gadchiroli"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Bhusari","sequence":"additional","affiliation":[{"name":"Gadchiroli Maharashtra Stroke Trial Project Gadchiroli"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Logade","sequence":"additional","affiliation":[{"name":"Gadchiroli Maharashtra Stroke Trial Project Gadchiroli"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu","family":"Nila","sequence":"additional","affiliation":[{"name":"Gadchiroli Maharashtra Stroke Trial Project Gadchiroli"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoummo","family":"Sen Gupta","sequence":"additional","affiliation":[{"name":"Gadchiroli Maharashtra Stroke Trial Project Gadchiroli"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Jadhav","sequence":"additional","affiliation":[{"name":"Gadchiroli Maharashtra Stroke Trial Project Gadchiroli"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref1","first-page":"1204-1222","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"396","author":"T Vos","year":"2020 Oct 17","journal-title":"Lancet."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"171-179","DOI":"10.1159\/000506396","article-title":"Global, Regional and Country-Specific Burden of Ischaemic Stroke, Intracerebral Haemorrhage and Subarachnoid Haemorrhage: A Systematic Analysis of the Global Burden of Disease Study 2017.","volume":"54","author":"R Krishnamurthi","year":"2020","journal-title":"Neuroepidemiology."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"161-176","DOI":"10.1159\/000441085","article-title":"Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study.","volume":"45","author":"V Feigin","year":"2015","journal-title":"Neuroepidemiology."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1764-1768","DOI":"10.1161\/STROKEAHA.115.008918","article-title":"Stroke Is the Leading Cause of Death in Rural Gadchiroli, India: A Prospective Community-Based Study.","volume":"46","author":"Y Kalkonde","year":"2015 Jul","journal-title":"Stroke."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1522-1529","DOI":"10.1093\/ije\/dyl168","article-title":"Chronic diseases now a leading cause of death in rural India--mortality data from the Andhra Pradesh Rural Health Initiative.","volume":"35","author":"R Joshi","year":"2006 Dec","journal-title":"Int. J. Epidemiol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e914-e923","DOI":"10.1016\/S2214-109X(18)30242-0","article-title":"Divergent Trends in Ischemic Heart Disease and Stroke Mortality in India from 2000 to 2015: A Nationally-Representative Mortality Survey. Lancet.","volume":"6","author":"C Ke","year":"2018;Aug","journal-title":"Glob. Health."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"541-543","DOI":"10.1111\/j.1747-4949.2011.00680.x","article-title":"Alternative therapies for stroke treatment in Asia.","volume":"6","author":"J Pandian","year":"2011 Dec","journal-title":"Int. J. Stroke."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"53-62","DOI":"10.1055\/s-0039-1700601","article-title":"Stroke Happens Suddenly so It Cannot Be Prevented: A Qualitative Study to Understand Knowledge, Attitudes, and Practices about Stroke in Rural Gadchiroli, Maharashtra, India.","volume":"11","author":"Y Kalkonde","year":"2020 Jan","journal-title":"J Neurosci Rural Pract."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"913-924","DOI":"10.1016\/S1474-4422(16)30073-4","article-title":"Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.","volume":"15","author":"V Feigin","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"761-775","DOI":"10.1016\/S0140-6736(16)30506-2","article-title":"Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.","volume":"388","author":"M O\u2019Donnell","year":"2016 Aug 20","journal-title":"Lancet."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e86043","DOI":"10.1371\/journal.pone.0086043","article-title":"Socio-demographic inequalities in the prevalence, diagnosis and management of hypertension in India: analysis of nationally-representative survey data.","volume":"9","author":"K Moser","year":"2014 Jan 23","journal-title":"PLoS ONE."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e1002801","DOI":"10.1371\/journal.pmed.1002801","article-title":"Hypertension screening, awareness, treatment, and control in India: A nationally representative cross-sectional study among individuals aged 15 to 49 years.","volume":"16","author":"J Prenissl","year":"2019 May 3","journal-title":"PLoS Med."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"596-603","DOI":"10.1089\/dia.2014.0018","article-title":"Glycemic control among individuals with self-reported diabetes in India--the ICMR-INDIAB Study.","volume":"16","author":"R Unnikrishnan","year":"2014 Sep","journal-title":"Diabetes Technol. Ther."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.12688\/wellcomeopenres.16377.1","article-title":"Gaps in secondary prevention among stroke survivors in rural Gadchiroli, India: a community-based cross-sectional study.","volume":"5","author":"Y Kalkonde","year":"2020","journal-title":"Wellcome Open Res."},{"key":"ref15","article-title":"Census of India: Area And Population.","year":"cited 2021 Oct 19"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1186\/s13063-019-3870-x","article-title":"Effect of a community-based intervention for cardiovascular risk factor control on stroke mortality in rural Gadchiroli, India: study protocol for a cluster randomised controlled trial.","volume":"20","author":"Y Kalkonde","year":"2019 Dec 23","journal-title":"Trials."},{"key":"ref17","article-title":"Transformation of Aspirational Districts-NITI Ayog India.","year":"cited 2021 Oct 19"},{"key":"ref18","article-title":"District Gadchiroli, Government of Maharashtra.","year":"cited 2021 Oct 19"},{"key":"ref19","article-title":"Collectorate Gadchiroli: District at a glance.","year":"cited 2021 Oct 19"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"97-105","DOI":"10.1038\/sj.jhh.1001642","article-title":"Impact of the high-risk and mass strategies on hypertension control and stroke mortality in primary health care.","volume":"18","author":"T Lin","year":"2004 Feb","journal-title":"J. Hum. Hypertens."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"235-239","DOI":"10.1159\/000444487","article-title":"High Prevalence of Stroke in Rural Gadchiroli, India: A Community-Based Study.","volume":"46","author":"Y Kalkonde","year":"2016","journal-title":"Neuroepidemiology."},{"key":"ref23","article-title":"WHO STEPS Stroke Manual.","year":"cited 2021 Oct 19"},{"key":"ref24","first-page":"19-23","article-title":"Tobacco vs Development: Private Spending on Tobacco in Gadchiroli District.","volume":"XLVIII","author":"S Sawalkar","year":"2013 Feb 2","journal-title":"Econ. Polit. Wkly."},{"key":"ref42","article-title":"Health Care Professional\u2019s Manual for Assigning Causes of Death Based in RHIME Household Reports. CGHR [Internet].","year":"cited 2026 Jun 27"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"741-748","DOI":"10.1093\/ije\/dyi181","article-title":"Validation of verbal autopsy procedures for adult deaths in China.","volume":"35","author":"G Yang","year":"2006 Jun","journal-title":"Int. J. Epidemiol."},{"key":"ref26","first-page":"90-94","article-title":"Validity of verbal autopsy in determining causes of adult deaths.","volume":"50","author":"R Kumar","year":"2006 Jun","journal-title":"Indian J. Public Health."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"319-326","DOI":"10.1093\/ije\/28.2.319","article-title":"Simple sample size calculation for cluster-randomized trials.","volume":"28","author":"R Hayes","year":"1999 Apr","journal-title":"Int. J. Epidemiol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"575-587","DOI":"10.1038\/s41371-018-0117-3","article-title":"Emerging trends in hypertension epidemiology in India.","volume":"33","author":"R Gupta","year":"2019 Aug","journal-title":"J. Hum. Hypertens."},{"key":"ref30","article-title":"GBD Compare|IHME Viz Hub.","year":"cited 2021 Oct 19"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"717-726","DOI":"10.1056\/NEJMoa1911965","article-title":"A Community-Based Intervention for Managing Hypertension in Rural South Asia.","volume":"382","author":"T Jafar","year":"2020 Feb 20","journal-title":"N. Engl. J. Med."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1231-1242","DOI":"10.1016\/S0140-6736(19)31949-X","article-title":"A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial.","volume":"394","author":"J Schwalm","year":"2019 Oct 5","journal-title":"Lancet."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1304-1314","DOI":"10.1056\/NEJMoa2509958","article-title":"Home-Based Care for Hypertension in Rural South Africa.","volume":"393","author":"M Siedner","year":"2025 Oct 2","journal-title":"N. Engl. J. Med."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e1004632","DOI":"10.1371\/journal.pmed.1004632","article-title":"Community health worker\u2013facilitated telehealth for moderate\u2013severe hypertension care in Kenya and Uganda: A randomized controlled trial.","volume":"22","author":"M Hickey","year":"2025 Jun 5","journal-title":"PLoS Med."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e761-e771","DOI":"10.1016\/S2214-109X(19)30077-4","article-title":"Task sharing with non-physician health-care workers for management of blood pressure in low-income and middle-income countries: a systematic review and meta-analysis.","volume":"7","author":"T Anand","year":"2019 Jun","journal-title":"Lancet Glob. Health."},{"key":"ref36","article-title":"Operational Guidelines. Ministry of Health and Family Welfare. Government of India.","year":"cited 2025 Nov 7"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"CD002091","DOI":"10.1002\/14651858.CD002091.pub2","article-title":"Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Stroke Group, editor.","volume":"2009","author":"B Manktelow","year":"2009 Jul 8 cited 2025 Mar 15","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1641-1649","DOI":"10.1016\/S0140-6736(97)04010-5","article-title":"CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.","volume":"349","year":"1997 Jun 7","journal-title":"Lancet."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1569-1581","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.","volume":"349","year":"1997 May 31","journal-title":"Lancet."},{"key":"ref40","article-title":"SDG Indicators.","year":"cited 2021 Oct 19"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.17605\/OSF.IO\/7Q5TJ","article-title":"Effect of a community-based intervention for cardiovascular risk factor control on stroke mortality in rural Gadchiroli, India: a cluster-randomised controlled trial-supplementary material.","author":"Y Kalkonde","year":"2026"}],"container-title":["Wellcome Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/11-209\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/11-209\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/11-209\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:34:10Z","timestamp":1790130850000},"score":1,"resource":{"primary":{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/11-209\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":40,"URL":"https:\/\/doi.org\/10.12688\/wellcomeopenres.26002.2","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/wellcomeopenres.26002.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.21956\/wellcomeopenres.29934.r167292","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/wellcomeopenres.29934.r167292","asserted-by":"object"}]},"ISSN":["2398-502X"],"issn-type":[{"value":"2398-502X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"Indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/11-209\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.21956\/wellcomeopenres.28619.r157585, Jeemon Panniyammakal, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, 23 Jun 2026, version 1, 1 approved, 1 approved with reservations","URL":"https:\/\/wellcomeopenresearch.org\/articles\/11-209\/v1#referee-response-157585","order":0,"name":"referee-response-157585","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Yogeshwar Kalkonde<\/b>; \n<i>Posted: 29 Jun 2026<\/i>; Conducting a large cluster randomised controlled trial in resource-poor settings to evaluate a community health worker-led intervention for stroke prevention is a remarkable achievement. Such trials are methodologically challenging and require extensive coordination across communities and health systems. The study provides robust evidence for scalable, community-based strategies that have the potential to substantially reduce stroke mortality in the long-term and improve population health in underserved settings. \n<b><i>Re: We thank the reviewer for these positive comments.<\/i><\/b>  I have the following comments:&nbsp; 1. Provide reasons for excluding 9 clusters from randomisation in the PRISMA flow chart. Explain it in the manuscript text.&nbsp; \n<b><i>Re: There were 73 eligible clusters available. The study protocol required only 64 clusters. A computer randomly selected 64 of the 73. The remaining 9 were simply not selected for inclusion. We have now edited the PRISMA flow chart and specified that they were not selected for inclusion. <\/i><\/b>  2. Primary outcome data: Please clearly mention whether you have primary outcome data from the migrated individuals. If yes, modify the numbers accordingly.&nbsp; \n<b><i>Re: Thank you for pointing this out. We do not have primary outcome data on migrated individuals. We have now specified this clearly in the Results section of the manuscript. <\/i><\/b>  3. The statistician involved in the randomisation and conducted the analysis: Is it the same individual? Please clearly explain the independent nature of the randomisation procedure.&nbsp; \n<b><i>Re: The statistician involved in randomisation and analyses were different. We have now specified this in the Randomization and blinding section under Methods. <\/i><\/b>  4. When was the randomisation done? Is it after the completion of all baseline data collection from all clusters? Please explain.&nbsp; \n<b>Re: Randomization was performed before baseline data collection. Baseline data were collected in randomized villages. We have now specified this in <i>the Randomization and blinding section under Methods.<\/i><\/b> &nbsp; 5. Who collected information on mortality and administered the VA tool? Explain the VA technique, analysis and final validation procedures.&nbsp; \n<b>Re: A team of trained field supervisors who were separate from the implementation team administered the VA tool. We have now described the VA technique, analysis and validation procedure in the Outcomes section under the Methods and added one reference for clarity.<\/b>  6. Describe the intervention using TIDieR checklist and provide it in the online supplement.&nbsp; \n<b><i>Re: We have now described the intervention using the TIDieR checklist and provided it as an online supplement.<\/i><\/b>  7. What was the cluster size assumed in the sample size calculation? Did you include a term for variation in cluster size? \n<b><i>Re: The cluster size assumed in the sample size calculation was 1200 with 16% of the cluster population above the age of 50 based on prior data from the demographic surveillance system. We used between-cluster correlation coefficient of variation to account for variation in cluster size as described in the Methods section. <\/i><\/b>","URL":"https:\/\/wellcomeopenresearch.org\/articles\/11-209\/v2#referee-comment-6636","order":1,"name":"referee-comment-6636","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/wellcomeopenres.28619.r157579, Jiale Zhang, China Academy of Chinese Medical Sciences, Beijing, 24 Jun 2026, version 1, 1 approved, 1 approved with reservations","URL":"https:\/\/wellcomeopenresearch.org\/articles\/11-209\/v1#referee-response-157579","order":2,"name":"referee-response-157579","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Yogeshwar Kalkonde<\/b>; \n<i>Posted: 29 Jun 2026<\/i>; The trial was powered to detect a 40% reduction in stroke mortality over the final 2.5 years, but the observed reduction was 16% (HR 0.84, p=0.23). The post-hoc analysis showing a 25% reduction over the entire 3.5 years (HR 0.75, p=0.022) is intriguing but should be clearly labelled as exploratory, as it was not pre-specified. I recommend that the Abstract and Conclusions place greater emphasis on the negative primary outcome, while acknowledging the post-hoc finding as hypothesis-generating. The current phrasing (&quot;there was a reduction... but this reduction was not significant&quot;) may inadvertently overstate the clinical certainty of benefit. \n<b><i>Re: We have now reworded the lines in the abstract as \u2013 \u201cAfter the intervention, the stroke mortality rate per 100,000 person-years in the last 2.5 years of the intervention, which was the primary outcome of the trial, was comparable in the intervention (416.7) and the control arm (484.9) (adjusted hazard ration [HR] 0.84, 95 % confidence interval [0.62,1.12]; p=0.23)\u201d.&nbsp; The abstract and Conclusions already highlight negative primary outcome. We have not included the description of post-hoc analysis in the abstract. We have also edited the results section to highlight negative primary outcome.<\/i><\/b>  The authors acknowledge limited access to brain imaging as a limitation. From a clinical standpoint, this is particularly relevant for the use of aspirin in secondary prevention without CT confirmation. While the authors cite large studies suggesting safety, the risk of giving aspirin to patients with undiagnosed intracerebral haemorrhage remains a real clinical concern in this setting. I would encourage the authors to elaborate on how they clinically excluded haemorrhagic stroke, and whether any adverse events related to aspirin use were systematically monitored and reported. \n<b><i>Re: Stroke patients who had loss of consciousness or seizures at the onset of symptoms were presumed to have had a haemorrhagic stroke and were not given aspirin. We have reported this information in the trial protocol but have added in the procedure section of the manuscript now. As a precautionary measure, we did monitor adverse events related to aspirin use among all users. These were systematically recorded and monitored by the external Data and Safety Monitoring Committee. No excessive adverse events were observed. We have now added this information to the limitations section under discussions. Supplementary table S12 also provides information on serious adverse events among patients with stroke.<\/i><\/b>  The gradual rollout of the NP-NCD in control villages during the trial period is an important confounder. The authors note that screening and treatment access improved in the control arm, which may have attenuated the observed mortality difference. This is a strength of the trial design (it reflects real-world conditions), but it also means the intervention effect may be underestimated. I would suggest that the Discussion more explicitly quantify the potential dilution effect\u2014for example, by estimating the proportion of control participants who received NP-NCD services\u2014and comment on how this might inform the interpretation of the non-significant primary outcome. \n<b><i>Re: We appreciate the reviewer's suggestion. We agree that exposure to services under the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD) could potentially attenuate the observed intervention effect. However, we were unable to quantify this dilution because exposure to NP-NCD services cannot be meaningfully classified as a binary variable. NP-NCD comprises a basket of services across the continuum of care like screening, referral, diagnosis and treatment. The care seeking in the real world was dynamic rather than linear. For example, a participant in the control arm may have been screened through NP-NCD but subsequently diagnosed and treated by a private provider; another may have been diagnosed by a private provider and later received treatment through NP-NCD; while others may have been referred by NP-NCD but never completed the referral pathway. Also, the surveys in the trial were not designed to capture individual-level exposure to routine NP-NCD services, making retrospective estimation unreliable. Hence, while we agree with the reviewer that efforts should be made to quantify the effect of NP-NCD, it is difficult to reliably estimate the proportion of control participants who 'received NP-NCD services' using the available data. We have now clarified this part in the limitations part in the Discussion section. <\/i><\/b>  The intervention involved monthly home visits by CHWs, outreach physician visits every 2\u20134 months, and free medications delivered at the village level. This level of intensity may be difficult to sustain within routine public health systems, even if it is clinically effective. The authors argue that such intensity is justified in low-literacy settings, which is reasonable. However, I would appreciate a more pragmatic discussion of how this model could be scaled with existing human resources (e.g., one ASHA per village is already overburdened with maternal and child health duties). What is the minimum effective dose of the intervention that could be realistically integrated into the NP-NCD? \n<b><i>Re:<\/i><\/b> \n<b><i>We thank the reviewer for these comments.<\/i><\/b> \n<b><i>The intervention evaluated in this study was deliberately intensive, incorporating monthly community health worker visits, periodic physician outreach, and village-level medication delivery to address well-recognised barriers to chronic disease care in rural, low-literacy settings. Also, our study was designed to evaluate the effectiveness of the intervention package rather than to identify the contribution of individual components. Determination of minimum effective dose that could be integrated into NP-NCD would need further implementation research which can explore making medications available in villages, risk-stratified follow-ups (e.g. those with blood pressure &gt;160\/100 or those who have both hypertension and diabetes, those with poor medication compliance), reduced visit frequency by the CHWs after initial disease control, greater use of facility-based NP-NCD services for stable patients. Such optimisation studies would help identify delivery models that balance effectiveness with feasibility within existing health system resources. We have now added a few lines in the Discussion section to elaborate more on this point.<\/i><\/b> &nbsp; Minor points: The trial registration (CTRI\/2015\/12\/006424) is provided, but the authors should confirm that all pre-specified outcomes are reported in accordance with the protocol. \n<b><i>Re: Thank you. We have now confirmed this in the last paragraph of the Methods section.<\/i><\/b>  The supplementary tables are comprehensive, but some key figures (e.g., medication compliance over time, adverse event rates) would be helpful in the main text to support the claim that the intervention was acceptable and safe. \n<b><i>Re: Thank you. We have now moved figures on medication compliance and serious adverse events to the main text.<\/i><\/b>  The delay in pu blication is acknowledged. I appreciate the transparency, and the reasons provided (COVID-19, institutional changes) are understandable. The results remain relevant given the ongoing scale-up of NP-NCD in India. \n<b><i>Re: We thank the reviewer for these positive comments.<\/i><\/b>  Overall conclusion: This is a commendable effort in a challenging setting. The trial demonstrates that a community-based, task-shared intervention is feasible and acceptable, and it improves blood pressure control and awareness. The lack of a statistically significant reduction in the primary outcome should not be seen as a failure\u2014it provides important lessons for future trial design, including the need for longer intervention periods, larger sample sizes, and accounting for concurrent policy changes. The findings will inform the ongoing refinement of non-communicable disease programmes in India and other LMICs. \n<b><i>Re: We thank the reviewer for the overall positive comments on the study.<\/i><\/b>","URL":"https:\/\/wellcomeopenresearch.org\/articles\/11-209\/v2#referee-comment-6637","order":3,"name":"referee-comment-6637","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/wellcomeopenres.29934.r167292, Giridhara R Babu, Qatar University, Doha, 23 Sep 2026, version 2, indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/11-209\/v2#referee-response-167292","order":4,"name":"referee-response-167292","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The trial was funded by the Wellcome Trust\/DBT India Alliance (https:\/\/www.indiaalliance.org) grant (IA\/CPHI\/14\/1\/501514). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":5,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}